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Research in Context 
 
Evidence before this study 
Before undertaking this study, the authors searched the published literature in PUBMED for 
evidence on remissions of type 2 diabetes, using all potential interventions.   For the present 
analysis, the authors reviewed new literature on remissions of type 2 diabetes through weight 
management, searching PUBMED since publication of the 12 month results of DiRECT (December 
2017) using search terms: clinical trial, remission, type 2 diabetes, weight loss.  The search revealed 
8 titles, of which only 3 indicated weight loss interventions.  Two of these were to DiRECT, and one 
to results from laparoscopic surgery, which was deemed not relevant.  
 
Added Value of this study 
The present study extends to 2 years evidence for durable remissions of type 2 diabetes following 
diet-induced weight loss.  Wider benefits relating to blood pressure, blood lipids, and well-being are 
demonstrated. It provides an increasingly confident answer to the top research question posed by 
people with type diabetes in the Diabetes UK/James Lind Alliance survey (published in The Lancet 
2017): ‘Can type 2 diabetes be cured or reversed?’ 
 
Implications of all the available evidence 
This study will provide added impetus to extend the early measures already announced to change 
existing NHS policy and practice for the routine management of type 2 diabetes.  The present data, 
and other relevant data on diabetes control, HbA1c and weight management all point towards the 
likelihood that intensive weight management has the potential to reduce or delay complications of 
diabetes and improve clinical outcomes. 
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ABSTRACT    
Background: DiRECT reported diabetes remission at one year for 46% of participants allocated to an 
integrated structured weight management programme.  We now assess two-year findings.  
Methods: DiRECT is an open-label, cluster-randomised, controlled trial in primary care practices 
randomised to a weight management programme (intervention) or best-practice care by guidelines 
(control). We recruited individuals aged 20–65 years, with <6 years duration of type 2 diabetes, 
body-mass index 27–45 kg/m2, and not receiving insulin. The intervention comprised withdrawal of 
anti-diabetes and antihypertensive drugs, total diet replacement (825–853 kcal/day formula diet) for 
12-20 weeks, stepped food reintroduction (2–8 weeks), and then structured support for weight loss 
maintenance.  Co-primary outcomes, analysed hierarchically, were weight loss >15 kg, and remission 
of diabetes, defined as HbA1c <6·5% (<48 mmol/mol) with no anti-diabetes medications.   
Findings: At 24 months, 53/149 (35·6%) of those commencing the intervention and 5/149 (3·4%) in 
the control group (adjusted odds ratio 25·8, 95% CI 8·3,80·8; p<0·0001) had remission, and 11·4% of 
intervention and 2·0% of the control group (adjusted odds ratio 8·2 (2·2,30·0), p=0·0015) had weight 
loss ≥15kg. Of those maintaining ≥10kg weight loss (45/272), 64% (29/45) achieved remission, and 
24.2% (36/149) of the intervention group maintained ≥10kg weight loss. Adjusted mean differences 
between groups were, in changes in body weight -5·4 kg, (-6·9,-4·0), p<0·0001, in HbA1c  -4·8 
mmol/mol, (-8·3,-1·4), p=0·0063 despite >50% fewer anti-diabetes agent use in intervention group, 
and SBP  -3·4 mmHg, (-6·7,-0·2), p=0·0397. Serious adverse events were similar at 12 months, but 
fewer occurred in intervention than control in the second year (9 vs. 22). Quality of life improved 
more from baseline in the intervention than the control group, adjusted mean difference 4·6 
(0·4,8·9, p=0·032). 
Interpretation:  This programme sustained remissions at 24 months for over a third of people with 
type 2 diabetes.  Weight loss of ≥10 kg provides remission for two thirds. 
Funding:  Diabetes UK.  
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Introduction 
The Diabetes Remission Clinical Trial (DiRECT) demonstrated that almost half (46%) of a group with 
type 2 diabetes up to 6 years duration could achieve remission at 12 months, by following a 
structured weight management programme 1 , and for 86% of those in the intervention group who 
achieved target weight loss of 15kg or more. These results have changed perceptions of a condition 
previously assumed to be permanent and demanding life-long drug treatment.  Between one in 16 
to 1 in 10 adults in the UK and US, respectively have type 2 diabetes 2,3, with much higher rates (up 
to 1 in 5) in other parts of the world4.  Diabetes complications are common and expensive to manage 
so associated healthcare costs are enormous despite the improvements offered through application 
of clinical guidelines. It is particularly devastating for the growing numbers of younger people 
affected, who tend to be more obese and lose more life-years through disabling and painful 
complications.5   
The extreme strength of association between excess weight gain in adult life and type 2 diabetes 
makes a causal relationship highly likely. The specific importance of intra-abdominal fat and large 
waist circumference has been long recognised, and the twin cycle mechanism, driven by a damaging 
but reversible accumulation of ectopic fat within the liver and pancreas in susceptible individuals, 
has now been consistently observed. 6–8 Several studies have now shown that weight loss of at least 
10-15 kg frequently normalises blood glucose in people with short-duration type 2 diabetes, and 
DiRECT did this in a real-life primary care setting. 9-12 
The major current questions are whether remissions can be durable and delivered at scale to reach 
the large numbers of patients, in primary care where they are usually managed, and then the extent 
to which vascular complications of diabetes can be delayed or avoided.  Sufficient weight loss for 
remission, of over 10-15 kg, can be achieved in various ways, including bariatric surgery but also 
using a low-calorie formula for total diet replacement.  The key issue now is how best to support 
long term maintenance of weight loss and remissions of diabetes. This is the greatest problem faced 
Draft 7   7th Feb 2019 
by individuals, and still misunderstood and requiring specific research, as in the past formula diets 
were  commonly regarded as effective only in the very short-term 13  
DiRECT was designed to test an integrated weight management programme delivered in primary 
care, with an initial period of effective weight loss, stepped food reintroduction with emphasis on 
energy balance, and then structured support for weight loss maintenance with provision for relapse 
management. We now report the clinical outcomes in the intervention and control groups at two 
years.  
Methods 
Study design and participants 
DiRECT is a two-year open-label, cluster-randomised controlled trial.  Ethics approval was granted by 
West 3 Ethics Committee in January, 2014, with approvals by the National Health Service (NHS) 
Health Boards in Scotland and Clinical Commissioning Groups in Tyneside. The trial is registered with 
the ISRCTN registry, number 03267836. 
The protocol, including details of recruitment methods, study conduct, and planned analyses, has 
been published elsewhere,14 as have the baseline characteristics of the groups.15 In brief, between 
2014-2016, we recruited individuals aged 20–65 years, diagnosed with type 2 diabetes within the 
past 6 years, body-mass index 27–45 kg/m2, and not receiving insulin.  The intervention programme 
(Counterweight-Plus), delivered entirely within a routine primary care setting by a trained NHS 
dietitian or nurse (as available locally), comprised total diet replacement (825–853 kcal/day formula 
diet) for 3–5 months (flexible duration to allow for individual goals and circumstances), stepped food 
reintroduction (6–8 weeks), and then structured support for weight loss maintenance. For the 
maintenance phase up to 24 months, participants were offered monthly 30 minute appointments 
with the dietitian or practice nurse, using tailored workbooks.  In the event of weight regain >2kg, 
participants were offered a ‘rescue plan’ of 2-4 weeks partial meal replacement, and if >4kg a total 
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diet replacement and food reintroduction, with the offer of orlistat treatment.  Advice to increase 
daily physical activity was reinforced at each visit although no specific targets were set. Both anti-
diabetic and antihypertensive drugs were withdrawn on day 1 of total diet replacement, with 
protocols for their reintroduction if necessary, according to clinical guidelines.  Antihypertensive 
drugs were withdrawn to avoid postural hypotension, as blood pressure generally decreases upon 
commencing a low energy diet.8  All participants provided written informed consent for the two-year 
study. 
Participants in both groups continued to receive diabetes care under current guidelines and 
standards from the National Institute of Health and Care Excellence in England 16 and the Scottish 
Intercollegiate Guidelines Network in Scotland.17 These guidelines do not at present include any 
recommendations for therapeutic  trials of medication withdrawal, which are left to the discretion of 
doctors in the event of clinical improvement through lifestyle changes.   All study appointments took 
place at the participants' own GP practices. 
Outcomes 
The co-primary outcomes were a reduction in weight of 15 kg or more, and remission of diabetes, 
defined as HbA1c less than 6·5% (<48 mmol/mol),18,19 from baseline to month 24. Secondary 
outcomes were quality of life, as measured by the EuroQol 5 Dimensions (EQ-5D-3L); serum lipids; 
and physical activity. Other pre-specified outcomes included programme acceptability, sleep quality, 
blood pressure, and serious adverse events collected from GP records, as detailed in the trial 
protocol.14  We additionally assessed changes in medications as exploratory outcomes.  Outcome 
data were collected at baseline and repeated at 12 and 24 months as planned.  All pre-specified 
outcomes are reported with the exception of exercise and sleep data which are not yet analysed.  
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For participants who ceased to engage, and did not attend their 12 or 24-month trial appointments, 
data from GP records (within a window of plus or minus 100 days of the scheduled follow-up date) 
were used, if available, as pre-specified in the protocol.15 
Statistical analysis 
The planned primary analyses were done at the individual level, according to the intention-to-treat 
principle. The co-primary outcomes were analysed in a hierarchical manner, the weight loss 
outcome first, with no adjustment of the p-values for multiple comparisons. For participants who did 
not attend the 12 or 24 month study assessment, and for whom data could not be obtained from GP 
records, we made the assumption that the primary outcomes were not met. For the main analysis of 
secondary outcomes, no assumptions were made regarding missing data.  
Sample-size calculations indicated that recruitment of 280 participants would be required to achieve 
80% power. These calculations assumed diabetes remission in 22% of participants in the 
intervention group at one year (the effect size deemed potentially important, a priori) compared 
with an estimated 5% in the control group, enrolment of ten participants per practice (fixed), an 
intra-class correlation coefficient of 0·05 to account for cluster randomisation, and an estimated 
dropout rate of 25% within 12 months. 
Outcomes were compared between groups with mixed-effects regression models, with adjustment 
for GP practice as a random effect. Logistic models were used for binary outcomes, and Gaussian 
models for continuous outcomes. If possible, models were adjusted for the minimisation variables 
(study centre and practice list size), age, sex, duration of diabetes and HbA1c at baseline. Models of 
continuous outcomes were also adjusted for the baseline measurement of the outcome. If models 
failed to converge, models with fewer adjustment variables were tried. For serum triglyceride, 
groups were compared with a linear regression model of log-transformed values, with adjustment 
for baseline log triglyceride. 
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For continuous outcomes, model fit was assessed visually with normal probability plots. When 
substantial departure from a normal distribution was observed, groups were also compared with 
non-parametric Wilcoxon or Mann–Whitney tests, using both the 24-month outcome value and the 
change from baseline. For binary outcomes, when the number of cases or non-cases was zero in one 
of the randomised groups and the regression model would not converge, we compared groups with 
Fisher's exact test. 
Statistical analyses were done with R for Windows, version 3.2.4.  
Role of the funding source 
The study funders had no role in study design, data collection, data analysis, interpretation, or 
writing of the report. All authors had full access to all the study data and the corresponding author 
had final responsibility for the decision to submit for publication. 
Results 
We recruited 306 individuals from 49 intervention (n=23) and control (n=26) practices, and the 
intention-to-treat population comprised 149 participants per group (Figure 1). Baseline 
characteristics were similar between groups.15 
A total of 116/149 (77·9%) participants in the intervention and 140/149 (94·0%) in the control group 
attended the 24 month study assessment, thus overall 42/298 (14·1%) randomised participants did 
not attend at 24 months. The baseline characteristics of those who attended this visit compared 
with those who did not are shown in Table S1. Additional data for weight and HbA1c were obtained 
from GP records where available, such that data at 24 months for body weight and for HbA1c were 
available for 272 (91·3%) participants (n=129 intervention and n=143 control).  For the intention-to-
treat analysis, the remaining 26 participants with no data at 24 months, who did not attend the 12 
or 24 month study assessment, and for whom GP records were not available because they had 
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moved residence or practice and could not be traced, were assumed not to have met either primary 
outcome (Figure 1). 
The intervention group participants attended an average of 7·7 monthly appointments during the 
second year (9·6 in those who attended the two-year follow-up visit). 
 
At 24 months, weight loss of 15 kg or more was observed in 17/129 (13·2%) intervention group 
participants (17/149, 11·4% of those commencing the intervention), and by 3/149 participants in the 
control group (adjusted odds ratio 7·49, 95% CI 2·05-27·32, p=0·0023, missing values imputed; Figure 
2A). In the intervention group 24.2% (36/149) maintained ≥10kg weight loss at 24 months. Absolute 
weight at each time point is shown in Table 1.  
At 24 months, without imputing missing data and assuming no remission for those without data, 
diabetes was in remission in 53/129 (41·1%) participants in the intervention group (35·6% of 149 
commencing the intervention) and 5/149 (3·4%) in the control group (adjusted odds ratio for 
imputed outcome 25·82, 95% confidence interval (8·25, 80·84); p<0·0001).   (Figure 2B). 
For the entire study population, remissions at 24 months were achieved by 8/154 (5.2%) participants 
who failed to achieve 5 kg weight loss, 21/73 (28·8%) who maintained 5–10 kg loss, 15/25 (60·0%) 
who maintained 10–15 kg loss, 29/45 (64·4%) who maintained ≥10kg loss, and 14/20 (70·0%) of 
participants who lost 15 kg or more (Figure 2C).  Four participants (out of 50 with weight gain (8·0%)) 
were in remission at both 12 and 24 months despite small weight gains (0-2kg) at 24 months. These 
individuals all had baseline Hba1c between 6.5% and 6.63%. Post-hoc analyses were conducted on 
the change in weight by achieved remission at each time point (Figure S1) and the baseline 
characteristics of those attending the 24 months visit compared with those who did not (Table S1).  
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Between baseline and 24 months, mean body weight fell by 7·6kg (SD 6·5) in the intervention group 
and by 2·3 kg (SD 5·2) in the control group (adjusted difference in weight change between groups at 
24 months of -5·43 kg, 95% CI -6·87 to -3·99; p<0·0001; Table 1).  
Between 12 and 24 months, mean body weight increased by 2·6 kg (SD 5·0) in the intervention 
group and decreased by 1·3 kg (SD 4·2) in the control group (adjusted difference in weight change 
between groups of 3·34 kg, 95% CI 2·18 to 4·50; p<0·0001). In the intervention group, those 
maintaining remission between 12 and 24 months (n=48), after having lost on average 15·51 kg (6·6) 
during year 1, regained on average 4·25 kg, SD 3·68. In those who relapsed after 12 months (n=15) 
weight regain was greater (7·09 kg (SD 5·42), t-test p=0·0732), after having lost an average of 11·98 
kg (SD 7·7). The group not in remission at 12 months (n=62 with weight data at both 12 and 24 
months) had an average weight gain of 0.26 kg (SD 4.7) after having lost 5·81 (SD 6·4) at 12 months. 
Over the 24 months from baseline, those who maintained remission lost an average of 10·4 kg (SD 
6·8),  those who were in remission at 12 months but relapsed at 24 months lost 3·7 kg (SD 5·9) and 
those who did not achieve remission at 12 or 24 months lost 3·2 (5·2) kg (Figure S1). Out of 143 
intervention arm participants who have data during treatment phases, about half required relapse 
management with brief total diet replacement and the offer of orlistat during the two years: 71 
(49·7%) had not had any ‘rescue plan’, 49 (34·3%) had one, 15 (10·5%) had two and 8 (5·6%) had 
three or more rescue plan phases.  The numbers of intervention arm participants receiving orlistat at 
12 and 24 months were 0 and 3 respectively. As the mean baseline weight was close to 100kg, 
similar patterns were recorded for BMI and for weight change expressed as a percentage of baseline 
weight. 
In the control group, mean HbA1c remained similar between baseline (58·2 mmol/mol, SD 11·5) and 
24 months (58·6, SD 14·4), with 115/149 (77·2%) receiving anti-diabetes medications at baseline, 
increasing to 120/143 (83·9%) at 24 months. In the intervention group, mean HbA1c fell between 
baseline (60·4, SD 13·7) and 24 months (54·4, SD 15·9), adjusted mean difference -4·82, (-8·28, -
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1·36), p=0·0063, with 111/149 (74·5%) receiving anti-diabetes medications at baseline and 51/129 
(39·5%) at 24 months.   
Mean systolic blood pressure at 24 months decreased by 1·4 mmHg (SD 13·4) in the control group 
and by 4·3 mmHg (SD 18·7) in the intervention group (adjusted mean difference -3·43, (-6·70, -0·16), 
p=0·0397), with 86/143 (60·1%) in the control group but only 61/129 (47·3%) in the intervention 
group receiving antihypertensive medication at 24 months (adjusted odds ratio 0·31, (0·14, 0·71), 
p=0·0058)(Table 1). 
Serum triglycerides at 24 months decreased below baseline values by 0·2 mmol/l (SD 0·7) in the 
control group and by 0·4 mmol/l (SD 1·2) in the intervention group (adjusted mean difference in log-
transformed values -0·14 (-0·23, -0·04), p=0·0055). 
Total serious adverse events reported for the first 24 months of DiRECT were 15 in the intervention 
and 25 in the control group, in 11 and 19 participants respectively.  While there had been no 
significant difference at 12 months, in the second year of DiRECT, six participants in the intervention 
group and 16 in the control group suffered nine and 22 serious adverse events respectively. None 
led to withdrawal from the study.  The serious adverse events (Table 2) included several vascular 
events in the control arm (two cerebral vascular accidents, one toe amputation, one aortic aneurysm 
rupture, and one sudden death), compared with one non-fatal MI in the intervention group in a 
person who had not attended for review. Two other serious adverse events, both in one participant 
during year one (cholelithiasis, abdominal pain), were deemed potentially related to the 
intervention.  
 
Quality of life assessed by visual analogue score at 24 months improved more in the intervention 
group (change from baseline 10·0 (0·0, 20·0) than in controls 2·5 (-5·0, 9·0); p=0·03)).  The absolute 
scores are shown in Table 1.  
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In the whole study population, likelihood of remission at 24 months (n=58/298, 19.5%) was higher 
for male sex (adjusted odds ratio for female vs. male 0·44 (0·22, 0·88), p=0·0196), and increased with 
age (adjusted odds ratio 1·08 (1·03, 1·13) per year, p=0·0020), , with weight loss from baseline 
(adjusted odds ratio 0·83 (0·77, 0·90) per kg, p<0·0001), and with weight-change from 12 to 24 
months (adjusted odds ratio per kg gained 1.11 (1·03, 1·21), p=0·0103).  Likelihood of remission at 24 
months was not influenced by baseline BMI (adjusted odds ratio per kg/m2 0·99 (0·92, 1·06), 
p=0·7701) or duration of diabetes within the 6-year range included (adjusted odds ratio per year 
0·92 (0·76, 1·11), p=0·3949). Where this could be assessed, the effects did not differ significantly 
between intervention and control group (p for interaction: sex p=0·3136, weight change from 12 to 
24 months p=0·4682, duration of diabetes within the 6 year range studied p=0·1144). All models 
were adjusted for treatment, practice list size, centre and a random effect for practice. 
 
Discussion 
The two-year results of DiRECT demonstrate that type 2 diabetes of up to 6 years' duration is not 
necessarily a permanent, lifelong, condition. Indeed, it is reversible to a durable remission, over 24 
months, for 64% of those who maintain a weight loss of over 10kg, and for 70% with weight 
loss >15kg. The evidence-based structured weight management programme, delivered by routine 
primary care staff in a community setting, achieved remissions at two years for over a third of those 
who commenced the intervention, and over 40% of those with two-year data. Achieving and 
maintaining weight loss is clearly the dominant factor behind remission of type diabetes, and 
participants reverting to diabetes between 12 and 24 months regained more weight than those 
maintaining remission. Weight regain was less than in many published studies13 but remains a 
challenge: the ambitious co-primary outcome of >15kg weight loss was maintained by only 11.4% by 
intention to treat analysis, down from 24% at 1 year. Blood pressure, lipids and quality of life 
improved with the intervention. DiRECT was not powered to assess ‘hard’ clinical outcomes, but 
seeing fewer serious adverse events in the second year of weight management is reassuring, given 
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the past anxiety over safety of older formula diets. The overall diabetes-related cardiometabolic risk 
profile improved, with reduced lipids and fewer participants requiring antihypertensive medications 
to control blood pressure than in the control group.   
DiRECT is the first study designed to test whether, and for how long, dietary weight loss can 
generate remission of type 2 diabetes . The programme used differs from many weight management 
treatments in its structured design, with a three-phase integrated structure, focussing from the 
outset on the need for long-term maintenance of weight loss. The observed weight regain and 
remission rates compare favourably with Look AHEAD20, which delivered an intensively supported 
programme in specialist US diabetes centres, combining considerable increases in physical activity 
and dietary programmes. Losing over 10kg in Look Ahead was associated with reduced 
cardiovascular events in a post hoc analysis. Remission of type 2 diabetes was not the primary 
outcome in Look Ahead, but  was observed in 9·2% at 2 years, with average weight loss of a little 
under 6kg.21  The DiRECT intervention has similarities with Look Ahead, but was designed specifically 
for achieving remissions, with a view to delivery at scale for the very large numbers of people with 
type 2 diabetes, therefore in a routine primary care setting. The results will help to overcome  
reluctance to offer weight management in primary care, whether through unfamiliarity with 
practical weight management or a belief that weight regain is inevitable and usually complete. 
Weight changes at 24 months in DiRECT are comparable to those reported using the same 
programme in a prospective audit of its routine use in other primary care and community settings, 
which found similar results for people with and without diabetes.22 The resources required for a 
programme based on the DiRECT intervention are not complicated or expensive, nor the training of 
routine staff burdensome. The 12-month intervention cost is under half of the average annual UK 
healthcare cost of a person with type 2 diabetes.23 These considerations, and the fact that DiRECT 
included a high proportion of participants from more socially deprived backgrounds 15 (unlike many 
other programs), all imply that the intervention should be widely transferable within routine 
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healthcare. Acceptability of the intervention is supported by a sustained modest, statistically 
significant improvement in quality of life.   
Bariatric surgery has dominated discussions of type 2 diabetes remission as an effective way of 
producing major weight loss and diabetes remissions.10–12 However, it is expensive and incurs risks of 
long-term problems, such as post-prandial hypoglycaemia, hypovolaemic dumping syndrome and 
micronutrient deficiencies that restrict acceptability.24,25 In addition, many people do not wish to 
undergo surgery.  The results of DiRECT and some previous studies26 challenge the view that the very 
large weight losses targeted by bariatric surgery are essential or optimal for sustained remission of 
type 2 diabetes. DiRECT provides the best evidence from a real-life trial of a non-surgical approach, 
but research into prevention of weight regain remains underdeveloped, and improved methods will 
be needed to match the long-term weight loss maintenance after surgery. Accumulated evidence 
points to duration of diabetes with earlier age of onset and persistent elevation of HbA1c as the 
main drivers of the disabling and costly clinical complications of type 2 diabetes, in particular the 
vascular consequences of associated hypertension and dyslipidaemia.27 The present observations on 
these improved cardiovascular risk factors are consistent with other evidence for clinical benefits 
from intentional weight loss for people with type 2 diabetes28.The potential advantages of remission 
are enormous but no long-term outcome data yet exist, other than after bariatric surgery. 9  
The present results suggest that type 2 diabetes is a clinical consequence of accumulation of excess 
weight, in ectopic sites by susceptible individuals, 17 even with a relatively low body mass index. The 
observation of changes in liver and pancreas fat which accompany weight loss with biochemical 
improvements in type 2 diabetes are consistent with this.29,8 It appears that failure to tackle that 
underlying process of fat accumulation allows diabetes to progress. Effective long-term weight 
management with a resetting of long-term energy consumption is clearly essential, but other factors 
contribute and there remain unanswered questions and debates about dietary approaches, and the 
optimal ratio of macronutrients. A recent study of people with type 2 diabetes has demonstrated 
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substantial weight loss, reduced glycaemia and decreased medications with a very low carbohydrate 
diet, although this was not randomised.30  However, meta-analyses of the controlled trial evidence 
show no important differences between high and low carbohydrate diets for weight control or 
HbA1c.31 Low intensity support and follow-up to establish longer term outcomes in DiRECT are 
currently funded to continue for all participants to a total of 3 years from baseline, and participants 
have consented to 5 years of follow up. While weight maintenance in DiRECT is better than in most 
previous studies, further research to optimise weight loss maintenance is essential. This could 
potentially incorporate other dietary methods, and medications if individually required, such as GLP-
1 agonists32 or non-pharmaceutical agents like inulin propionate ester 33 where appropriate and 
necessary for those who fail to maintain remissions long-term. The present results make a strong 
case that intensive weight management should be included as a first-line option in routine care for 
people with type 2 diabetes, to seek early remission from a potentially devastating progressive 
disease.18   
Some limitations and potential for bias are inevitable in research conducted in real-life settings. 
Although statisticians were blinded for the primary analysis, participants and clinicians in DiRECT 
were aware of their planned allocation to the control or intervention group, as the unit of 
randomisation was the primary care centre, to reduce contamination between groups. Following 
publication of the first-year results of DiRECT (December 20171) there was considerable media 
coverage which may have tended to attenuate the difference between the randomised groups. A 
proportion of the control group took personal action to lose weight (9 participants in the control 
group lost >10 kg during the second year compared to 2 during the first year). Increased use of SGLT-
2 inhibitors may also have contributed to the weight change in controls. At 12 months no control 
participants had achieved the co-primary outcome of weight loss greater than 15kg, but at 24 
months it was reached by 3 (2·1%), and there was a significant difference between the weight loss in 
the control group and weight gain in the intervention group. Despite this the differences in 
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remission and weight loss between groups were still highly significant and clinically important at 2 
years. Weight regain in the intervention group contributed to limit the effect size. The racial and 
ethnic characteristics, while typical of UK type 2 diabetes populations, do not allow for unqualified 
extrapolation to other groups, such as South Asians, who tend to develop diabetes with less weight 
gain (and may therefore need less weight loss to undergo remission). The conclusions reported here 
apply to people with type 2 diabetes diagnosed within the previous 6 years, and existing evidence 
has shown that remission, though still possible,  is less likely after longer durations of disease.8,10 As 
medication withdrawal is not part of standard guidelines, it has to be considered that some control 
participants might have been able to sustain HbA1c below the cut off for remission if their anti-
diabetic agents had been withdrawn. The strengths of the study include a well-defined intervention 
and a robust cluster-randomised study design, managed by a well-established clinical trials unit. The 
sample had characteristics very similar to the general population of people with type 2 diabetes, so 
the results are likely to be widely generalisable.15 The study was well powered for the co-primary 
outcomes of remission and weight change at the primary analysis point at 1 year and we now 
observe clinically meaningful outcomes at 2 years. Relating to this, the overall loss to follow up of 
14·1% over 2 years is modest for a weight loss study in real-life conditions.14  
In conclusion, the 2-year results of DiRECT confirm that type 2 diabetes is potentially reversible by 
weight loss in most cases.  A structured primary care weight management programme within 6 years 
of diagnosis can sustain remission to a non-diabetic state, off anti-diabetes drugs, for over a third of 
people with type 2 diabetes and over two thirds of those who lost more than 10kg at 24 months. 
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Legends to Figures 
 
Figure 1: Trial profile 
 
Figure 2: Primary outcomes and remission of diabetes in relation to weight loss at 12 and at 24 
months. Regression models adjusting for practice list size, study centre and a random effect for 
practice.  
A: First co-primary outcome, achievement of ≥15kg weight loss, by randomised group. B: Second co-
primary outcome, remission of diabetes (HbA1c <48mmol/mol, off anti-diabetic medication for 2 
months), by randomised group.  
C: Remission of diabetes, in relation to weight loss achieved (both randomised groups combined). 
 
Figure 3: Changes in weight of participants who remained in the trial and those who dropped out 
during each phase of the intervention.  
Error bars represent 95% CI 
 
 
Figure S1: Median weight change shown by remission status. Error bars represent interquartile 
range.
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Table 1: Key Secondary and other outcomes 
  N(c) 
Mean (SD) Intervention Effect at 24 months 
ICC 
Baseline 12 months 24months 
Change @ 
24 months 
Estimate 95% CI p-value 
Secondary Outcomes           
Weight (kg)  
Intervention 129 101·0 (16·7) 90·4 (16·4) 93·2 (17·2) -7·6 (6·5) 
-5·43 
(-6·87, -
3·99) 
p<0·0001 <0·01 
Control 143 98·8 (16·1) 97·7(16·4) 96·4 (16·3) -2·3 (5·2) 
HbA1c (mmol/mol) 
Intervention 129 60·4 (13·7) 50·6(13·3) 54·4 (15·9) -5·2 (16·4) 
-4·82 
(-8·28, -
1·36) 
p=0·0063 <0·01 
Control 143 58·2 (11·5) 59·6(12·1) 58·6 (14·4) 0·4 (15·5) 
HbA1c (%) 
Intervention 129 7·7 (1·3) 6·8(1·2) 7·1 (1·5) -0·5 (1·5) 
-0·44 
(-0·76, -
0·13) 
p=0·0063 <0·01 
Control 143 7·5 (1·1) 7·6(1·1) 7·5 (1·3) 0·0 (1·4) 
Number of prescribed oral 
antidiabetic medications(a) 
Intervention 129 1·1 (0·9) 0·4(0·7) 0·6 (0·9) -0·6 (0·8) 
-0·86 
(-1·02, -
0·69) 
p<0·0001 <0.01 
Control 143 1·1 (0·8) 1·3(0·9) 1·3 (1·0) 0·3 (0·6) 
Number of prescribed 
antihypertensive medications  
Intervention 129 1·0 (1·1) 0·5(0·7) 0·7 (0·9) -0·3 (0·9) 
-0·36 
(-0·53, -
0·19) 
p<0·0001 0·03 
Control 143 1·0 (1·1) 1·0(1·0) 1·1 (1·1) 0·1 (0·5) 
Systolic blood pressure 
(mmHg) 
Intervention 113 132·7 (17·5) 133·0(16·3) 130·3 (13·6) -4·3 (18·7) 
-3·43 
(-6·70, -
0·16) 
p=0·0397 0·01 
Control 140 137·2 (16·0) 135·8(14·6) 135·4 (14·0) -1·4 (13·4) 
EQ-5D Health Utility Score 
Intervention 113 
0·798 
(0·288) 
0·793(0·278) 0·819 
(0·268) 
-0·002 
(0·205) 
0·024 
(-0·021, 
0·070) 
p=0·2949 <0·01 
Control 140 
0·802 
(0·281) 
0·759 
(0·302) 
0·788 
(0·253) 
-0·013 
(0·194) 
Quality of Life Intervention 113 65·8 (19·1) 73·7(19·0) 75·2 (17·3) 8·2 (20·1) 4·64 (0·39, 8·89) p=0·0324 0·04 
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EQ-5D VAS Control 140 72·1 (19·6) 69·1(15·6) 74·0 (16·8) 1·7 (15·1) 
Other Outcomes           
Triglycerides (mmol/l) (b) 
Intervention 105 2·1 (1·4) 1·7 (1·4) 1·6 (1·0) -0·4 (1·2) 
-0·14 
(-0·23, -
0·04) 
p=0·0055 <0.01 
Control 138 1·9 (0·9) 2·0 (1·2) 1·7 (0·9) -0·2 (0·7) 
Binary outcomes   N (% of all available at this time point) 
 Odds 
Ratio 
95% CI p-value  
Number on any anti-diabetic 
medications 
Intervention 129 111 (74·5%) 39 (26·4%) 51 (39·5%)  
0·03 (0·01, 0·08) p<0·0001  
Control 143 115 (77·2%) 121 (81·8%) 120 (83·9%)  
 
Intervention effects reported as estimated mean differences (Intervention-Control), based on mixed effects linear regression model, adjusted for 
randomised group, baseline value, age, sex, duration of diabetes and HbA1c at baseline, study centre (Tyneside, Scotland), and practice list size 
(≤5700, >5700) as fixed effects, and GP practice as a random effect.  
N refers to number of participants with data available at 24 months for each outcome. ICC: Intraclass Correlation Coefficient. 
(a) Number (%) of participants prescribed 0, 1, or 2+ oral antidiabetic medications at 12 months were: Intervention – 109 (73·6%), 26 (17·6%), 13 (8·8%); 
Control – 27 (18·2%), 70 (47·3%), 51 (34·5%). 
(b) Log-transformed values were used in the regression analysis. 
(c) Number with data a 2 year follow-up 
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Table 2: Serious Adverse Events up to 24 months follow-up 
 
 All  Control Intervention 
Number of Participants 
306  149 157 
Number of SAEs 40  25 15 
Number (%) of participants with any SAE 30 (9·8%)  
19 
(12·8%) 
11 (7·0%) 
Number (%) of participants with any SAEs,classified by MedDRA System Organ Class (SOC) and 
Preferred Term (PT): 
 SOC: CARDIAC DISORDERS 4 (1·3%)  1 (0·7%) 3 (1·9%) 
 
PT: 
 
Acute myocardial infarction 
Angina pectoris 
Atrial fibrillation 
Coronary artery disease 
1 (0.3%) 
1 (0·3%) 
1 (0·3%) 
1 (0.3%) 
 
0 (0.0%) 
0 (0·0%) 
1 (0·7%) 
0 (0.0%) 
1 (0.6%) 
1 (0·6%) 
0 (0·0%) 
1 (0.6%) 
 SOC: GASTROINTESTINAL DISORDERS 4 (1·3%)  1 (0·7%) 3 (1·9%) 
 
PT: 
 
Abdominal pain 
Abdominal strangulated hernia 
Diverticulum 
Gastric disorder 
1 (0·3%) 
1 (0·3%) 
1 (0·3%) 
1 (0·3%) 
 
0 (0·0%) 
0 (0·0%) 
0 (0·0%) 
1 (0·7%) 
1 (0·6%) 
1 (0·6%) 
1 (0·6%) 
0 (0·0%) 
 SOC: 
GENERAL DISORDERS AND ADMINISTRATION 
SITE CONDITIONS 
1 (0·3%)  1 (0·7%) 0 (0·0%) 
 PT:  Sudden death 1 (0·3%)  1 (0·7%) 0 (0·0%) 
 SOC: HEPATOBILIARY DISORDERS 2 (0·7%)  1 (0·7%) 1 (0·6%) 
 
PT: 
 
Cholelithiasis 
Non-alcoholic steatohepatitis 
1 (0·3%) 
1 (0·3%) 
 
0 (0·0%) 
1 (0·7%) 
1 (0·6%) 
0 (0·0%) 
 SOC: INFECTIONS AND INFESTATIONS 5 (1·6%)  3 (2·0%) 2 (1·3%) 
 
PT: 
 
Arthritis bacterial 
Diverticulitis 
Urinary tract infection 
Wound infection 
1 (0·3%) 
2 (0·7%) 
1 (0·3%) 
1 (0.3%) 
 
1 (0·7%) 
1 (0·7%) 
0 (0·0%) 
1 (0.7%) 
0 (0·0%) 
1 (0·6%) 
1 (0·6%) 
0 (0.0%) 
 SOC: 
INJURY, POISONING AND PROCEDURAL 
COMPLICATIONS 
3 (1·0%)  1 (0·7%) 2 (1·3%) 
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 All  Control Intervention 
 
PT: 
 
Humerus fracture 
Incisional hernia 
Synovial rupture 
1 (0·3%) 
1 (0·3%) 
1 (0·3%) 
 
1 (0·7%) 
0 (0·0%) 
0 (0·0%) 
0 (0·0%) 
1 (0·6%) 
1 (0·6%) 
 SOC: 
MUSCULOSKELETAL AND CONNECTIVE 
TISSUE DISORDERS 
1 (0·3%)  1 (0·7%) 0 (0·0%) 
 PT:  Back pain 1 (0·3%)  1 (0·7%) 0 (0·0%) 
 SOC: 
NEOPLASMS BENIGN, MALIGNANT AND 
UNSPECIFIED (INCL CYSTS AND POLYPS) 
5 (1·6%)  5 (3·4%) 0 (0·0%) 
 
PT: 
 
Bladder cancer 
Colon cancer 
Prostate cancer 
Renal cell carcinoma 
1 (0·3%) 
2 (0·7%) 
1 (0·3%) 
1 (0·3%) 
 
1 (0·7%) 
2 (1·3%) 
1 (0·7%) 
1 (0·7%) 
0 (0·0%) 
0 (0·0%) 
0 (0·0%) 
0 (0·0%) 
 SOC: NERVOUS SYSTEM DISORDERS 6 (2.0%)  4 (2.7%) 2 (1.3%) 
 
PT: 
 
Cerebellar infarction 
Cerebrovascular accident 
Dizziness 
Guillain-Barre syndrome 
Presyncope 
Sciatica 
VIIth nerve paralysis 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
1 (0.3%) 
 
1 (0.7%) 
1 (0.7%) 
0 (0.0%) 
1 (0.7%) 
0 (0.0%) 
0 (0.0%) 
1 (0.7%) 
0 (0.0%) 
0 (0.0%) 
1 (0.6%) 
0 (0.0%) 
1 (0.6%) 
1 (0.6%) 
0 (0.0%) 
 SOC: 
PREGNANCY, PUERPERIUM AND PERINATAL 
CONDITIONS 
1 (0.3%)  0 (0.0%) 1 (0.6%) 
 PT:  HELLP syndrome 1 (0.3%)  0 (0.0%) 1 (0.6%) 
 SOC: 
RESPIRATORY, THORACIC AND MEDIASTINAL 
DISORDERS 
4 (1.3%)  4 (2.7%) 0 (0.0%) 
 
PT: 
 
Asthma 
Dyspnoea 
2 (0.7%) 
2 (0.7%) 
 
2 (1.3%) 
2 (1.3%) 
0 (0.0%) 
0 (0.0%) 
 SOC: SURGICAL AND MEDICAL PROCEDURES 1 (0.3%)  1 (0.7%) 0 (0.0%) 
 PT:  Toe amputation 1 (0.3%)  1 (0.7%) 0 (0.0%) 
 SOC: VASCULAR DISORDERS 1 (0.3%)  1 (0.7%) 0 (0.0%) 
 PT:  Aortic aneurysm rupture 1 (0.3%)  1 (0.7%) 0 (0.0%) 
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Table S1: Baseline characteristics by attendance of 2-year follow-up visit. ITT population. P-values 
have been derived using Wilcoxon tests or Exact Fisher tests, as appropriate. 
  All Did not attend Did attend p-value 
  N = 298 N = 41 N = 257  
Age (years) 
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298  
54.4 (7.6) 
55.1 
(49.2, 60.9) 
[30.8, 65.9] 
41  
49.2 (8.8) 
48.9 
(43.8, 54.3) 
[30.8, 65.4] 
257  
55.2 (7.0) 
55.6 
(50.6, 61.1) 
[32.4, 65.9] 
p<0.0001 W 
Sex 
 
Number 
N (%) Male 
N (%) Female 
298  
176 (59.1%) 
122 (40.9%) 
41  
21 (51.2%) 
20 (48.8%) 
257  
155 (60.3%) 
102 (39.7%) 
p=0.3064 F 
Years since diabetes diagnosis 
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298  
3.0 (1.7) 
3.0 
(1.5, 4.5) 
[0.0, 6.0] 
41  
2.1 (1.8) 
1.6 
(0.6, 3.5) 
[0.1, 5.8] 
257 
3.1 (1.7) 
3.1 
(1.7, 4.6) 
[0.0, 6.0] 
p=0.0001 W 
HbA1c (mmol/mol), from GP records 
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298  
61.6 (13.9) 
58.0 
(51.0, 68.0) 
[43.0, 107.0] 
41  
66.1 (16.8) 
62.0 
(52.0, 79.0) 
[44.0, 105.0] 
257 
60.9 (13.3) 
57.0 
(51.0, 67.0) 
[43.0, 107.0] 
p=0.0748 W 
HbA1c (%), from GP records 
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Table S1: Baseline characteristics by attendance of 2-year follow-up visit. ITT population. P-values 
have been derived using Wilcoxon tests or Exact Fisher tests, as appropriate. 
  All Did not attend Did attend p-value 
  N = 298 N = 41 N = 257  
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298  
7.79 (1.27) 
7.46 
(6.82, 8.37) 
[6.09, 11.94] 
41  
8.20 (1.54) 
7.82 
(6.91, 9.38) 
[6.18, 11.76] 
257  
7.72 (1.21) 
7.37 
(6.82, 8.28) 
[6.09, 11.94] 
p=0.0748 W 
Weight (kg) 
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298 (0) 
99.9 (16.4) 
99.0 
(87.7, 109.5) 
[67.0, 149.1] 
41 (0) 
101.7 (17.8) 
102.0 
(88.9, 109.7) 
[74.3, 146.7] 
257 (0) 
99.6 (16.2) 
98.7 
(87.6, 109.0) 
[67.0, 149.1] 
p=0.5234 W 
BMI (kg/m2) 
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298 (0) 
34.6 (4.4) 
34.1 
(31.1, 37.5) 
[27.3, 44.9] 
41 (0) 
35.4 (4.4) 
35.9 
(32.9, 38.4) 
[27.8, 44.9] 
257 (0) 
34.5 (4.4) 
34.0 
(30.8, 37.4) 
[27.3, 44.9] 
p=0.1813 W 
SBP (mmHg) 
 
Number 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
298 (0) 
134.9 (16.9) 
134.0 
(122.1, 144.0) 
[100.0, 194.5] 
41 (0) 
129.8 (17.9) 
128.0 
(119.0, 138.0) 
[100.0, 171.5] 
257 (0) 
135.8 (16.6) 
135.0 
(123.0, 145.0) 
[100.0, 194.5] 
p=0.0268 W 
History of Heart Failure 
 
Number 
N (%) Yes 
N (%) No 
298  
2 (0.7%) 
296 (99.3%) 
41  
2 (4.9%) 
39 (95.1%) 
257  
0 (0.0%) 
257 (100.0%) 
p=0.0185 F 
Albumin/Creatinine Ratio (mg/mmol) (values <0.5 imputed as 0.25) 
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Table S1: Baseline characteristics by attendance of 2-year follow-up visit. ITT population. P-values 
have been derived using Wilcoxon tests or Exact Fisher tests, as appropriate. 
  All Did not attend Did attend p-value 
  N = 298 N = 41 N = 257  
 
Nobs (Nmiss) 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
292 (6) 
2.16 (6.89) 
0.25 
(0.25, 1.38) 
[0.25, 89.97] 
37 (4) 
5.40 (15.37) 
0.84 
(0.25, 3.44) 
[0.25, 89.97] 
255 (2) 
1.69 (4.38) 
0.25 
(0.25, 1.20) 
[0.25, 46.85] 
p=0.0050 W 
Microalbuminuria, defined as ACR≥3.5 (female) or ACR≥2.5 (male) 
 
Nobs (Nmiss) 
N (%) No 
N (%) Yes 
292 (6) 
253 (86.6%) 
39 (13.4%) 
37 (4) 
26 (70.3%) 
11 (29.7%) 
255 (2) 
227 (89.0%) 
28 (11.0%) 
p=0.0040 F 
C-rP (mg/l) 
 
Nobs (Nmiss) 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
291 (7) 
3.33 (3.64) 
2.21 
(1.12, 4.32) 
[0.10, 32.09] 
37 (4) 
4.45 (4.25) 
3.29 
(1.95, 5.26) 
[0.51, 24.70] 
254 (3) 
3.17 (3.52) 
2.04 
(1.10, 3.86) 
[0.10, 32.09] 
p=0.0025 W 
HDL Cholesterol (mmol/l) 
 
Nobs (Nmiss) 
Mean (SD) 
Median 
(Q1, Q3) 
[Min, Max] 
291 (7) 
1.12 (0.28) 
1.09 
(0.92, 1.28) 
[0.35, 2.61] 
37 (4) 
1.02 (0.26) 
0.98 
(0.88, 1.15) 
[0.35, 1.72] 
254 (3) 
1.13 (0.28) 
1.11 
(0.94, 1.30) 
[0.40, 2.61] 
p=0.0149 W 
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Table S2 Summary of weight change from baseline by use of antidiabetic medications 
   Weight change at 
   12 Months 24 Months 
All participants   -5.3 (7.6), n=285 -4.8 (6.4), n=272 
On anti-diabetic medication at   
Baseline 12 Months 24 Months   
No No No -7.9 (7.1), n=45 -5.3 (5.2), n=44 
No No Yes -2.8 (5.3), n=7 -2.8 (4.3), n=8 
No Yes No -5.3 (-), n=1 -3.7 (-), n=1 
No Yes Yes -4.2 (5.6), n=7 -6.0 (3.9), n=7 
Yes No No -13.4 (8.3), n=52 -9.9 (7.5), n=53 
Yes No Yes -5.3 (6.7), n=14 -4.4 (2.7), n=16 
Yes Yes No 1.9 (5.2), n=2 3.3 (7.1), n=2 
Yes Yes Yes -1.8 (5.0), n=140 -3.0 (5.7), n=140 
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Table S3 Summary of weight change from baseline by use of anti-diabetic medications 
   Weight change at 
   12 Months 24 Months 
All   -5.3 (7.6), n=285 -4.8 (6.4), n=272 
On anti-diabetic medication at   
Baseline 12 Months 24 Months   
Intervention group 
No No No -11.7 (6.8), n=26 -7.8 (5.1), n=26 
No No Yes -3.7 (7.7), n=2 -4.2 (6.5), n=3 
No Yes No - (-), n=0 - (-), n=0 
No Yes Yes - (-), n=0 - (-), n=0 
Yes No No -13.7 (8.1), n=51 -10.1 (7.5), n=52 
Yes No Yes -5.3 (6.7), n=14 -4.4 (2.7), n=16 
Yes Yes No - (-), n=0 - (-), n=0 
Yes Yes Yes -6.4 (6.6), n=32 -5.5 (5.6), n=32 
Control group 
No No No -2.7 (3.2), n=19 -1.6 (2.4), n=18 
No No Yes -2.5 (5.2), n=5 -2.0 (2.8), n=5 
No Yes No -5.3 (-), n=1 -3.7 (-), n=1 
No Yes Yes -4.2 (5.6), n=7 -6.0 (3.9), n=7 
Yes No No -0.4 (-), n=1 -2.1 (-), n=1 
Yes No Yes - (-), n=0 - (-), n=0 
Yes Yes No 1.9 (5.2), n=2 3.3 (7.1), n=2 
Yes Yes Yes -0.5 (3.4), n=108 -2.3 (5.6), n=108 
 
 
